Journal of Anaesthesiology Clinical Pharmacology (Jan 2017)

Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery

  • Juan P Cata,
  • Vinny Singh,
  • Brenda M Lee,
  • John Villarreal,
  • John R Mehran,
  • J Yu,
  • Vijaya Gottumukkala,
  • Hagar Lavon,
  • Shamgar Ben-Eliyahu

DOI
https://doi.org/10.4103/joacp.JOACP_299_16
Journal volume & issue
Vol. 33, no. 3
pp. 317 – 323

Abstract

Read online

Background and Aims: The aim is to evaluate the association between the use of intraoperative dexmedetomidine with an increase in recurrence-free survival (RFS) and overall survival (OS) after nonsmall cell lung cancer (NSCLC) surgery. Material and Methods: This was a propensity score-matched (PSM) retrospective study. Single academic center. The study comprised patients with Stage I through IIIa NSCLC. Patients were excluded if they were younger than 18 years. Primary outcomes of the study were RFS and OS. RFS and OS were evaluated using univariate and multivariate Cox proportional hazards models after PSM (n = 251/group) to assess the association between intraoperative dexmedetomidine use and the primary outcomes. The value of P < 0.05 was considered statistically significant. Results: After PSM and adjusting for significant covariates, the multivariate analysis demonstrated no association between the use of dexmedetomidine and RFS (hazard ratio [HR] [95% confidence interval (CI)]: HR = 1.18, 95% CI: 0.91–1.53; P = 0.199). The multivariate analysis also demonstrated an association between the administration of dexmedetomidine and reduced OS (HR = 1.28, 95% CI: 1.03–1.59; P = 0.024). Conclusions: This study demonstrated that the intraoperative use of dexmedetomidine to NSCLC patients was not associated with a significant impact on RFS and but worsening OS. A randomized controlled study should be conducted to confirm the results of this study.

Keywords